Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Other financing activities (2024 - 2026)

Kestra Medical Technologies (KMTS) reported Other financing activities of $84000.0 for Q1 2026, up 21.74% year-over-year from $69000.0 in Q1 2025, and up 221.74% on a QoQ basis from -$69000.0 in Q2 2025.

Kestra Medical Technologies (KMTS) has 3 years of Other financing activities data on file, last reported at $84000.0 in Q1 2026.

  • Quarterly Other financing activities rose 21.74% year-over-year to $84000.0 in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $84000.0 (down 97.45% YoY) and the FY2025 annual result came in at $3.2 million, up 37.02% from the prior year.
  • Other financing activities rose to $84000.0 in Q1 2026 per KMTS's latest filing, from -$69000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $3.2 million in Q3 2024 and bottomed at -$69000.0 in Q2 2025.
  • The 3-year median for Other financing activities is $69000.0 (2025), against an average of $661800.0.
  • The widest annual swing landed in 2025, when Other financing activities sank 7000.0%; it then increased 21.74% in 2026.
  • Tracing KMTS's Other financing activities over 3 years: stood at $3.2 million in 2024, then sank by 102.14% to -$69000.0 in 2025, then jumped by 221.74% to $84000.0 in 2026.
  • Per Business Quant, the three latest KMTS Other financing activities figures stand at $84000.0 (Q1 2026), -$69000.0 (Q2 2025), and $69000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Kestra Medical Technologies 1.13 Bn 840.05 Mn 12.91 Mn

Historic Data

Download Data 🔒
DateValue
Jan 31, 2026 84,000.00
Jan 31, 2026 84,000.00
Apr 30, 2025 -69,000.00
Apr 30, 2025 -69,000.00
Jan 31, 2025 69,000.00
Jan 31, 2025 69,000.00
Jul 31, 2024 3.22 Mn
Jul 31, 2024 3.22 Mn
Apr 30, 2024 1,000.00
Apr 30, 2024 1,000.00